Contributor Disclosures for Neuroprotective Agents in Stroke
Role Name Disclosure Details
Author Helmi L Lutsep, MD, Associate Professor, Department of Neurology, Oregon Health and Science University; Associate Director, Oregon Stroke Center Co-Axia
Talecris
AGA Medical
Boehringer Ingelheim
Boston Scientific
Details
Coauthor Wayne M Clark, MD, Director of Oregon Stroke Center, Department of Neurology, Professor, Oregon Health Sciences University Nothing to discloseDetails
Medical Editor Frederick M Vincent, Sr, MD, Clinical Professor, Department of Neurology and Ophthalmology, Michigan State University Colleges of Human and Osteopathic Medicine Nothing to discloseDetails
Pharmacy Editor Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine Nothing to discloseDetails
Managing Editor Howard S Kirshner, MD, Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center Boehringer Ingelheim
BMS/Sanofi
Pfizer
Novartis
Details
CME Editor Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital Nothing to discloseDetails
Chief Editor Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants Nothing to discloseDetails






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Helmi L Lutsep

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Co-Axia
Consulting feeReview panel membership 
Talecris
Consulting feeReview panel membership 
AGA Medical
Consulting feeReview panel membership 
Boehringer Ingelheim
HonorariaSpeaking and teaching 
Boston Scientific
HonorariaSpeaking and teaching 
Off label or investigational use of medication
As part of clinical trials that are reviewed by the IRB









Contributor Disclosure


Contributor:
Contributor Disclosure:
Wayne M Clark, Coauthor  The contributor discloses no conflict of interest. 









Contributor Disclosure


Contributor:
Contributor Disclosure:
Frederick M Vincent,, Sr, Medical Editor  The contributor discloses no conflict of interest. 






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Francisco Talavera

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Howard S Kirshner

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Boehringer Ingelheim
HonorariaSpeaking and teaching 
BMS/Sanofi
HonorariaSpeaking and teaching 
Pfizer
HonorariaSpeaking and teaching 
Novartis
Consulting feeReview panel membership 
Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Selim R Benbadis

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Nicholas Y Lorenzo

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication